BioSpace News Archive

Augmedics, a pioneer in augmented reality surgical image guidance, has announced its groundbreaking xvision Spine System has been successfully used for the first time in a spinal fusion surgery in the United States. The system was used in a spinal surgery procedure by Joh

The Biotechnology Innovation Organization (BIO) today released its ninth biennial report, “ The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities ,” which highlights Michigan as a top state for the biosciences. The report studies the state of the U.S. bioscience industry and its associated inno

Approximately 7.5 million people in the U.S.1 have psoriasis, a chronic inflammatory disease that mostly affects the skin and joints but could also affect the nails.

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, announced the signing of three new European distributor agreements to promote HTG products and services in Nordic and Eastern European Countries with BioNordika, Explorea, and ELTA 90.

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due to public health and safety concerns related to the outbreak of the novel coronavirus (“COVID-19"), and to support the health and well-being of its stockholders, employees and oth

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a hum

The Board of Directors of Bristol Myers Squibb (NYSE:BMY) today declared a quarterly dividend of forty-five cents ($0.45) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 3, 2020, to stockholders of record at the close of business on July 6, 2020. The directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible

Immunomic Therapeutics, Inc. will present preclinical data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice. UNITE fuses a tumor-associated

VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatment options, today announced that results from the company’s VAST study, a 12-month trial evaluating VIA Disc®, a non-surgical, injectable intradiscal treatment option for patients suffering from degenerative disc disease (DDD), will be presented at The Orthobiologic Institute’s (TOBI) virtual 11th Annual Orthobiologics Symposium

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that it intends to rely on exemptions granted in Ontario Instrument 51-505 Temporary Exemption from Certain Corporate Finance Requirements